Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02124512 · ClinicalTrials.gov registry record · Phase 2
Blood Lipopolysaccharide (LPS) Rifaximin Study
A Phase 2 study, sponsored by Philip Kern.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02124512 is a Phase 2 study that has completed, run by Philip Kern. The registered enrollment target is 12 participants.
The verdict
NCT02124512, a Phase 2 study, has completed, sponsored by Philip Kern.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Metabolic syndrome is a condition involving elevated levels of fat in the blood, a tendency towards diabetes, hypertension, and too much fat around the abdomen (an increased waistline). Individuals with metabolic syndrome often have impaired glucose tolerance, which is a condition where blood sugar is normal when fasting (before eating), but is too high after drinking a sugary drink. This is due to an abnormality in the body's sensitivity to insulin (insulin resistance), which is due in part to an inability of the muscle to take up glucose. People with metabolic syndrome have inflammation in their fat tissue and in their blood stream, and the changes in the level of inflammatory chemicals produced by cells in your fat tissues will be studied. One possible source of the inflammation may be the bacteria in the intestine. When individuals eat fatty foods, some of the bacterial products become attached to the fat in their blood and then get directed to fat tissue. The investigators wish to determine whether individuals have an excessive amount of inflammation in their fat tissues, and whether this inflammation comes from the bacteria in their intestines. To determine this, the investigators wish to treat individuals with an antibiotic that reduces the bacteria in their intestines and in their blood, and determine whether this reduces their overall level of inflammation.
Interventions
- OTHER Placebo
- DRUG Rifaximin SSD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02124512
The ClinicalTrials.gov registry entry for NCT02124512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philip Kern, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02124512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02124512 about?
NCT02124512 is a clinical study titled "Blood Lipopolysaccharide (LPS) Rifaximin Study". Metabolic syndrome is a condition involving elevated levels of fat in the blood, a tendency towards diabetes, hypertension, and too much fat around the abdomen (an increased waistline). Individuals with metabolic syndrome often have impaired glucose tolerance, which is a condition where blood sugar ...
What is the current status of trial NCT02124512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2015-03. Estimated completion is 2019-05-31.
What interventions are being tested in trial NCT02124512?
The interventions under investigation include: Placebo (OTHER), Rifaximin SSD (DRUG).
Who is sponsoring clinical trial NCT02124512?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.